September
1
Exagen Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients
SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...
News
Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.